When following current COG ALL protocols with the addition of two courses of blinatumomab to treatment for SR and HR patients, how frequently should surveillance bone marrow and MRD evaluations be performed?

When following current COG ALL protocols and amendments that include the addition of two courses of blinatumomab to SR and HR, how frequently should surveillance bone marrow aspiration and MRD by clonoSEQ be performed?

• EOI and EOC
• EOI, EOC, during maintenance before end of therapy
• EOI, EOC, End of ID, End of therapy
• EOI, EOC, after earch cycle of blinat, end of ID, End of therapy
• Other